Cargando…

Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is increasingly recognized as a persistent disorder requiring long-term management. OBJECTIVES: Our objective was to evaluate the 2-year safety and efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents with ADHD. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coghill, David R., Banaschewski, Tobias, Nagy, Peter, Otero, Isabel Hernández, Soutullo, César, Yan, Brian, Caballero, Beatriz, Zuddas, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511319/ https://www.ncbi.nlm.nih.gov/pubmed/28667569 http://dx.doi.org/10.1007/s40263-017-0443-y

Ejemplares similares

Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Banaschewski, Tobias, et al.
Publicado: (2018)

Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2018)

Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial
por: Coghill, David R, et al.
Publicado: (2014)

Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder
por: Banaschewski, Tobias, et al.
Publicado: (2013)

A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2014)

A Post Hoc Comparison of the Effects of Lisdexamfetamine Dimesylate and Osmotic-Release Oral System Methylphenidate on Symptoms of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Soutullo, César, et al.
Publicado: (2013)

Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial
por: Coghill, David R., et al.
Publicado: (2013)

Relative Bioavailabilities of Lisdexamfetamine Dimesylate and d-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink
por: Ermer, James, et al.
Publicado: (2016)

Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Banaschewski, Tobias, et al.
Publicado: (2014)

Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa
por: Dixon, Laura, et al.
Publicado: (2023)

The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA
por: Ágh, Tamás, et al.
Publicado: (2016)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Treatment Response and Remission in a Double-Blind, Randomized, Head-to-Head Study of Lisdexamfetamine Dimesylate and Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder
por: Dittmann, Ralf W., et al.
Publicado: (2014)

Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa
por: Dixon, Laura, et al.
Publicado: (2023)

Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study
por: Dittmann, Ralf W., et al.
Publicado: (2013)

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe
por: Siffel, Csaba, et al.
Publicado: (2020)

Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate
por: Nagy, Peter, et al.
Publicado: (2015)

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
por: Pennick, Michael
Publicado: (2010)

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
por: Ermer, James C., et al.
Publicado: (2016)

Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
por: Najib, Jadwiga, et al.
Publicado: (2017)

Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020)

An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults
por: Ermer, James, et al.
Publicado: (2013)

Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study
por: Ermer, James, et al.
Publicado: (2015)

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
por: Richards, Cynthia, et al.
Publicado: (2018)

Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder
por: Coghill, David R., et al.
Publicado: (2017)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009)

Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder
por: Griffiths, Kristi R., et al.
Publicado: (2021)

A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
por: Gasior, Maria, et al.
Publicado: (2017)

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2022)

Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use
por: Jain, Rakesh, et al.
Publicado: (2013)

Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2019)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
por: Zimovetz, Evelina A., et al.
Publicado: (2017)

Identification, Characterization and Quantification of Process-Related and Degradation Impurities in Lisdexamfetamine Dimesylate: Identifiction of Two New Compounds
por: Gao, Shenghua, et al.
Publicado: (2018)

Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2020)

Influence of Lisdexamfetamine Dimesylate on Early Ejaculation—Results from a Double-Blind Randomized Clinical Trial
por: Haghighi, Mohammad, et al.
Publicado: (2021)

Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donors*
por: Pennick, Michael
Publicado: (2013)

Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol
por: Griffiths, Kristi R., et al.
Publicado: (2019)

Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
por: Yee, Karen S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s1mvau4t1brfjqkr6ic88nck1i